Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 deaths in 27 countries since 2012. There are no approved treatments for MERS-CoV infection although a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evaluated in humans in the Kingdom of Saudi Arabia. Here, we show that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro. In mice, both prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and severe lung pathology. In contrast, prophylactic LPV/RTV-IFNb slightly reduces viral loads without impacting other disease parameters. Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce virus replication or severe lung pathology. Thus, we provide in vivo evidence of the potential for RDV to treat MERS-CoV infections.

Cited by papers we hold 42

• Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study · 2022
  Not checked
• Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay · 2022
  No notice
• Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms · 2022
  No notice
• An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come? · 2021
  Not checked
• COVID-19 and cardiovascular system—a comprehensive review · 2021
  Not checked
• The Clinical Characteristics and Treatment Approaches of COVID-19:A Concise Review · 2021
  Not checked
• Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges · 2021
  Not checked
• Therapeutic approaches against coronaviruses acute respiratory syndrome · 2021
  Not checked
• Impact of repurposed drugs on the symptomatic COVID-19 patients · 2021
  Not checked
• Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19 · 2021
  No notice
• Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 · 2021
  No notice
• COVID-19: breaking down a global health crisis · 2021
  No notice
• Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies · 2021
  No notice
• COVID-19 Therapeutic Options Under Investigation · 2020
  Not checked
• Causal Therapy of COVID-19: Critical Review and Prospects · 2020
  Not checked
• COVID-19: The biology behind the virion · 2020
  Not checked
• Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia · 2020
  Not checked
• Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past · 2020
  No notice
• Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations · 2020
  No notice
• A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs · 2020
  Not checked

and 22 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.